Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase

[1]  W. P. Dixon,et al.  BMPD statistical software manual , 1988 .

[2]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[3]  Harold T. Dodge,et al.  Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .

[4]  S. Sherry,et al.  High-dose, brief-duration intravenous infusion of streptokinase in acute myocardial infarction: description of effects in the circulation. , 1986, The American journal of cardiology.

[5]  I. Palacios,et al.  Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. , 1986, Circulation.

[6]  E. Braunwald,et al.  Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. , 1986, Circulation.

[7]  E. Topol,et al.  Coronary thrombolysis with recombinant tissue-type plasminogen activator. A hematologic and pharmacologic study. , 1985, Annals of internal medicine.

[8]  D. Collen,et al.  Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. , 1985, The Journal of pharmacology and experimental therapeutics.

[9]  E. Braunwald,et al.  High dose intravenous streptokinase for acute myocardial infarction: preliminary results of a multicenter trial. , 1985, Journal of the American College of Cardiology.

[10]  R. Steiner,et al.  Inhibition of platelet function by contrast media: iopamidol and ioxaglate versus iothalamate. Work in progress. , 1985, Radiology.

[11]  R. W. Brower,et al.  RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator , 1985, The Lancet.

[12]  K. Rentrop,et al.  Thrombolytic therapy in patients with acute myocardial infarction. , 1985, Circulation.

[13]  A. Schafer,et al.  Plasmin inhibition of platelet function and of arachidonic acid metabolism. , 1985, The Journal of clinical investigation.

[14]  M. Verstraete,et al.  Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates. , 1985, The Journal of clinical investigation.

[15]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[16]  B E Sobel,et al.  Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. , 1984, Circulation.

[17]  J. J. Spadaro,et al.  Coronary thrombolysis with recombinant human tissue-type plasminogen activator. , 1984, Circulation.

[18]  E. Braunwald,et al.  Thrombolytic therapy. A new strategy for the treatment of acute myocardial infarction (1). , 1984, The New England journal of medicine.

[19]  G. Timmis,et al.  Hemorrhage and the products of fibrinogen digestion after intracoronary administration of streptokinase. , 1984, Circulation.

[20]  F. Van de Werf,et al.  Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. , 1984, The New England journal of medicine.

[21]  E. Braunwald,et al.  Thrombolytic therapy: a new strategy for the treatment of acute myocardial infarction (second of two parts) , 1984 .

[22]  M. Ter-pogossian,et al.  Clot-selective coronary thrombolysis with tissue-type plasminogen activator. , 1983, Science.

[23]  G. Vetrovec,et al.  Fibrinolytic Effects of Intracoronary Streptokinase Administration in Patients with Acute Myocardial Infarction and Coronary Insufficiency , 1983, Circulation.

[24]  P. Seeburg,et al.  Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli , 1983, Nature.

[25]  A. Billiau,et al.  Purification of Human Tissue-Type Plasminogen Activator in Centigram Quantities from Human Melanoma Cell Culture Fluid and Its Conditioning for Use In Vivo , 1982, Thrombosis and Haemostasis.

[26]  C. Korninger,et al.  Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis. , 1982, The Journal of clinical investigation.

[27]  J. Hermans,et al.  Fibrin: Structure and Interactions , 1982, Seminars in thrombosis and hemostasis.

[28]  M S Golden,et al.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.

[29]  U. Gafter,et al.  Inhibition of platelet aggregation by contrast media. , 1979, Radiology.

[30]  N. Ardaillou,et al.  Biological Effects of Fibrinogen-Fibrin Degradation Products , 1975, Thrombosis and Haemostasis.

[31]  G. W. Snedecor.  STATISTICAL METHODS , 1967 .

[32]  R. Berry,et al.  MICROMETHOD FOR THE ESTIMATION OF PLASMA FIBRINOGEN. , 1965, Clinical chemistry.